[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acquired-immunodeficiency-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acquired-immunodeficiency-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,76,106,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100053374","fuyang-jiedu-granules-plus-antiretroviral-therapy-for-hiv-immune-non-responders-with-spleen-kidney-yang-deficiency-100053374",false,"NCT07698548","Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency","A Pragmatic Randomized Controlled Trial of Fuyang Jiedu Granules Combined With Antiretroviral Therapy for Immune Reconstitution Failure in People With HIV and Spleen-Kidney Yang Deficiency Syndrome","FYJD-INR-pRCT","Inclusion Criteria:Aged 18 to 60 years, male or female. CD4+ T lymphocyte count \\\u003C350 cells\u002FuL. Meets diagnostic criteria for HIV-1 infection according to the Chinese Guidelines for Diagnosis and Treatment of HIV\u002FAIDS (2024 edition).\n\nMeets diagnostic criteria for incomplete immune reconstitution: ART for more than 4 years; peripheral blood viral load below the lower limit of detection (\\\u003C50 copies\u002FmL) for more than 3 years; persistent CD4+ T-cell count \\\u003C350 cells\u002FuL; and exclusion of other causes of long-term low CD4+ T-cell count.\n\nMeets the Traditional Chinese Medicine diagnostic criteria for spleen-kidney yang deficiency syndrome, supported by the designated four-diagnostic instrument (model SZY-ZM-1) where applicable.\n\nVoluntarily agrees to participate and signs informed consent. -\n\nExclusion Criteria:Uncontrolled acute or chronic physical or mental illness. Poor adherence to ART. WBC \\\u003C2 x 10\\^9\u002FL, neutrophils \\\u003C1.0 x 10\\^9\u002FL, hemoglobin \\\u003C90 g\u002FL, platelets \\\u003C75 x 10\\^9\u002FL, or abnormal hepatic\u002Frenal function. Hepatic abnormality is defined as AST, ALT, or total bilirubin \\>=2 times the upper limit of normal; renal abnormality is defined as creatinine clearance below the normal value.\n\nOther serious comorbid disease, such as tumor, cirrhosis, or cardiovascular\u002Fcerebrovascular disease.\n\nPregnancy, lactation, or recent plan for pregnancy\u002Fchildbearing. Use of immunosuppressants or immunomodulators within 6 months before screening. Any other condition judged by the investigator to make the participant unsuitable for the study.\n\n\\-","ALL","18 Years","60 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","This pragmatic randomized controlled trial evaluates whether Fuyang Jiedu Granules combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and spleen-kidney yang deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Fuyang Jiedu Granules plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.",[28,29,30,31,32],"HIV-1 Infection","Acquired Immunodeficiency Syndrome","Immune Reconstitution Failure","Immunological Non-responder","Spleen-Kidney Yang Deficiency Syndrome",[34,35,36,37,38,39,40,41,42,43],"HIV","AIDS","immune non-responder","incomplete immune reconstitution","ART","CD4+ T cell","Traditional Chinese Medicine","Fuyang Jiedu Granules","pragmatic randomized controlled trial","pRCT","NOT_YET_RECRUITING","2026-07-07",{"date":47,"type":48},"2026-07-13","ACTUAL",{"date":50,"type":22},"2026-08",{"date":52,"type":22},"2029-02",{"name":54,"class":55},"Beijing University of Chinese Medicine","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":75,"locationsCount":56},"100053530","qiling-yiqi-tablets-plus-antiretroviral-therapy-for-hiv-immune-non-responders-with-lung-spleen-qi-deficiency-100053530","NCT07698574","Qiling Yiqi Tablets Plus Antiretroviral Therapy for HIV Immune Non-responders With Lung-Spleen Qi Deficiency","A Pragmatic Randomized Controlled Trial of Qiling Yiqi Tablets Combined With Antiretroviral Therapy for Immune Reconstitution Failure in People With HIV and Lung-Spleen Qi Deficiency Syndrome","QLYQ-INR-pRCT","Inclusion Criteria:Aged 18 to 60 years, male or female. CD4+ T lymphocyte count \\\u003C350 cells\u002FuL. Meets diagnostic criteria for HIV-1 infection according to the Chinese Guidelines for Diagnosis and Treatment of HIV\u002FAIDS (2024 edition).\n\nMeets diagnostic criteria for incomplete immune reconstitution: ART for more than 4 years; peripheral blood viral load below the lower limit of detection (\\\u003C50 copies\u002FmL) for more than 3 years; persistent CD4+ T-cell count \\\u003C350 cells\u002FuL; and exclusion of other causes of long-term low CD4+ T-cell count.\n\nMeets the Traditional Chinese Medicine diagnostic criteria for lung-spleen qi deficiency syndrome, supported by the designated four-diagnostic instrument (model SZY-ZM-1) where applicable.\n\nVoluntarily agrees to participate and signs informed consent. -\n\nExclusion Criteria:Uncontrolled acute or chronic physical or mental illness. Poor adherence to ART. WBC \\\u003C2 x 10\\^9\u002FL, neutrophils \\\u003C1.0 x 10\\^9\u002FL, hemoglobin \\\u003C90 g\u002FL, platelets \\\u003C75 x 10\\^9\u002FL, or abnormal hepatic\u002Frenal function. Hepatic abnormality is defined as AST, ALT, or total bilirubin \\>=2 times the upper limit of normal; renal abnormality is defined as creatinine clearance below the normal value.\n\nOther serious comorbid disease, such as tumor, cirrhosis, or cardiovascular\u002Fcerebrovascular disease.\n\nPregnancy, lactation, or recent plan for pregnancy\u002Fchildbearing. Use of immunosuppressants or immunomodulators within 6 months before screening. Any other condition judged by the investigator to make the participant unsuitable for the study.\n\n\\-",{"count":21,"type":22},[25],"This pragmatic randomized controlled trial evaluates whether Qiling Yiqi Tablets combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and lung-spleen qi deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Qiling Yiqi Tablets plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.",[28,29,30,31,69],"Lung-Spleen Qi Deficiency Syndrome",[34,35,36,37,38,39,40,71,42,43],"Qiling Yiqi Tablets",{"date":47,"type":48},{"date":50,"type":22},{"date":52,"type":22},{"name":54,"class":55},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":56},"100245918","phase-2-cytotoxic-t-lymphocytes-in-treating-patients-with-malignancies-with-bk-andor-jc-virus-100245918","NCT02479698","Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and\u002For JC Virus","Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection","Inclusion Criteria:\n\n* Patients ≥ 2 years. English and non-English speaking patients are eligible.\n* Immunocompromised patients; and\u002For Non-immunocompromised patients with PML\u002FJC virus Encephalitis; and\u002For patients with any type of malignancies; and\u002For HIV\u002FAIDs; and\u002For history of solid organ transplant; and\u002For Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per RECIST criteria.\n* Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood PCR positive for BK virus and\u002For JC viral encephalitis and\u002For JC end-organ disease and\u002For polyomavirus.\n* Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg\u002Fkg\u002Fday of prednisone.\n* Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion.\n* Written informed consent and\u002For signed assent from patient, parent or guardian. Patients with cognitive impairments are eligible.\n* Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\n* Patients enrolled on this study may be enrolled on other IND studies at the discretion of the PI.\n* Patients may be re-enrolled in the protocol should the infection re-occur, provided they meet all the other eligibility criteria at the moment of re-enrollment.\n\nExclusion Criteria:\n\n* Patients receiving prednisone \\> 0.5 mg\u002Fkg\u002Fday at time of enrollment, or have received ATG within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment.\n* Patients with other uncontrolled infections (except HIV\u002FAIDS). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection\n* Patients with active acute (GVHD) grades II-IV",{"count":84,"type":22},100,[86],"PHASE2","This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and\u002For JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and\u002For JC virus.",[29,89,90,91,92,93,94,95],"BK Virus Infection","Human Immunodeficiency Virus","JC Virus Infection","Malignant Neoplasm","Merkel Cell Carcinoma","Merkel Cell Polyomavirus Infection","Viral Encephalitis","RECRUITING","2026-06-10",{"date":99,"type":48},"2026-06-12",{"date":101,"type":48},"2015-07-23",{"date":103,"type":22},"2027-07-31",{"name":105,"class":55},"M.D. Anderson Cancer Center",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100537605","a-multicenter-prospective-clinical-cohort-study-on-the-pathogen-spectrum-of-hivaids-complicated-with-infection-100537605","NCT06280001","A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV\u002FAIDS Complicated With Infection","Inclusion Criteria:\n\n1. Sign the informed consent form.\n2. HIV positive.\n3. Any gender, age 18 to 70 years old\n\nExclusion Criteria:\n\n1.Patients deemed unsuitable by the investigator to participate in the study.","70 Years",{"count":114,"type":22},500,"OBSERVATIONAL","The goal of this observational study is to determine the incidence and spectrum of opportunistic infections among Chinese HIV\u002FAIDS patients at this stage, to find intervention targets, to construct an early warning prediction model, and to give an individualized program with integrated immune function to obtain salvage opportunities for patients.The main questions it aims to answer are:\n\n* Describe the populations and characteristics of pathogenic microorganisms involved in HIV co-infection, map the spatial and temporal changes in the infection system of pathogenic microorganisms, and evaluate their impact on disease regression.\n* Explore the mechanism of interaction between pathogenic microorganisms and host autoimmune deficiencies.\n* Discover early warning and predictive markers and immunological indicators of pathogenic microorganisms, and explore new technologies and programs to reduce the mortality rate of infection.",[29,118],"HIV Infections",[120,121,122],"Infection","Pathogen spectrum","Cohort study","2024-03-01",{"date":125,"type":48},"2024-03-04",{"date":127,"type":22},"2024-03",{"date":129,"type":22},"2026-11",{"name":131,"class":55},"Zhejiang University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100477208","phase-4-efficacy-and-tolerability-of-dtg-plus-3tc-in-hiv-infected-adults-with-virologically-suppression-and-tdf-toxicity-100477208","NCT05493969","Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity","A Study Evaluating the Efficacy and Tolerability of Dolutegravir Plus Lamivudine in HIV Infected Adults Who Are Virologically Suppressed and With Evidence of TDF Toxicity","Inclusion Criteria:\n\n1. Female subjects were required to meet one of the following criteria: 1) Incapacitated, defined as postmenopausal (spontaneous amenorrhea at 12 months, age ≥45 years) or physically unable to conceive after tubal ligation, hysterectomy, or bilateral oophorectomy; 2) Have potential to have children, but are negative at screening and on day 1 pregnancy test, and agree to use appropriate contraceptive methods, including oral contraceptives, condoms and intrauterine devices;\n2. At least once plasma HIV-1 RNA\\\u003C40 c\u002FmL in the 6 months prior to screening and plasma HIV-1 RNA \\\u003C40 c\u002FmL at screening;\n3. Must be on uninterrupted TDF + 3TC\u002FFTC-based regimen for ≥6 months prior to screening;\n4. Participants with pre-existing clinical manifestations of TDF related adverse reactions at the time of screening.\n\n   TDF-related renal damage was defined as: meeting 1 of the 5 following conditions in the investigator's judgement, based upon the medical history and relevant examinations, likely to represent TDF toxicity:\n\n   i. eGFR decrease by 5 mL\u002Fmin per year for at least 3 consecutive years or confirmed 25% eGFR decline from baseline ii. Urine β2-microglobulin\u002FCr ≥300 μg\u002Fg iii. Urine microalbumin\u002Fcreatinine \\>30 μg\u002Fmg iv. Non-diabetic glycosuria (urine glucose 1+ or above) v. Serum phosphate \\\u003C0.8 mmol\u002FL TDF - associated bone toxicity is defined as a T-value less than -1.0 or Z- value less than -2.0 or fragility fracture after TDF\u002FXTC use and other factors is excluded according to the medical history and relevant examination.\n5. Sign the informed consent and be able to visit regularly according to the test requirements.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study;\n2. Participants with AIDS-related opportunistic infections or AIDS-related or unrelated neoplastic diseases;\n3. Patients with ALT \\>= 5 x ULN, or ALT \\>=3 x ULN and bilirubin \\>= 1.5xULN (with \\>35% direct bilirubin. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n4. Evidence of Hepatitis B virus (HBV) infection: Participants positive for HBsAg, negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded.\n5. Hepatitis C virus (HCV) infection;\n6. Participants who are allergic or intolerant to lamivudine or dolutegravir;\n7. Participants with known previous episodes of virologic failure and known resistance mutations of 3TC or INSTI if resistance mutations had previously been identified;\n8. Taking medications that contraindicated with lamivudine or dolutegravir; Other conditions that the investigator considers unsuitable to participate in the study, including the risk of suicide, poor adherence, and interference with the evaluation of clinical study endpoints.\n9. Participants with creatinine clearance \\\u003C30ml\u002Fmin.","75 Years",{"count":84,"type":22},[142],"PHASE4","To investigate the efficacy and tolerability of the regimen of dolutegravir plus lamivudine in HIV infected adults who are virologically suppressed and with evidence of TDF toxicity.",[29],"2022-08-06",{"date":147,"type":48},"2022-08-09",{"date":149,"type":22},"2022-08",{"date":151,"type":22},"2026-06",{"name":153,"class":154},"Shanghai Public Health Clinical Center","OTHER_GOV"]